Covid 19 Research using Clinical Trials (Home Page)
Report for D003231: Conjunctivitis NIH
(Synonyms: Conjunctivitis)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (5)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug736 | Schirmer Test I Wiki | 1.00 |
| drug382 | Hydroxychloroquine Sulfate 400 mg twice a day Wiki | 1.00 |
| drug384 | Hydroxychloroquine Sulfate 600 mg twice a day Wiki | 1.00 |
| drug383 | Hydroxychloroquine Sulfate 600 mg once a day Wiki | 1.00 |
| drug627 | Placebo oral tablet Wiki | 0.22 |
Correlated MeSH Terms (0)
| Name (Synonyms) | Correlation |
|---|
Correlated HPO Terms (0)
| Name (Synonyms) | Correlation |
|---|
There is one clinical trial.
Clinical Trials
1 Tear Fluid miRNA Analysis in Sars-Cov2 Conjunctivitis
The aim of this study is to assess the virus RNA, and miRNA levels related to viral infection, and inflammatory response in tears of hospitalized patients with a diagnosis of COVID-19 with and without conjunctivitis and to correlate them with clinical condition. Tears will be collected by using Schirmer Test I, a non invasive painless test which can be performed at the patient's bed. Tears will be collected on the graduated paper strips pulling the lower lid gently downward for 5 minutes. Following, the strip will be placed in a 2.0 mL Eppendorf tube and stored at −80◦C (or - 20°C)
NCT04346160 COVID Conjunctivitis Diagnostic Test: Schirmer Test I MeSH:Conjunctivitis
HPO:Conjunctivitis
Primary Outcomes
Description: - to asses virus RNA and miRNA levels in tears
Measure: virus molecular analysis Time: 2 weeks
Description: - to asses inflammatory response molecules
Measure: host molecular analysis Time: 2 weeks
Secondary Outcomes
Description: To analyze the prevalence of conjunctivitis in patients with a diagnosis of COVID-19 and the assessment of the predictive value of conjunctivitis in the development of the COVID-19 disease (or in developing respiratory distress forms-ARDS).
Measure: Epidemiologic data Time: 2 weeks
HPO Nodes
HP:0000509: Conjunctivitis
Genes 116
GTF2H5 BLNK CCR1 ERCC2 FGFR2 IARS2 XPA ERCC2 BTK PSMB9 FOXC2 ERF TP63 CD79B MPLKIP TARS1 XPC NLRP3 CD19 ERCC2 TFRC LMNA ERAP1 UROS WIPF1 LRBA HLA-B TP63 GJB6 GSN SAMD9 TNFRSF13B PLG LRRC8A ICOS FOXE3 MBTPS2 MPLKIP GNAS IGLL1 NLRP3 RNF113A TNFRSF13C ERCC3 RNF125 GATA1 CD79A NOD2 TP63 CD19 CR2 FOXC2 FAS AIRE NLRP3 NLRC4 WAS PSMB8 PSMB4 HLA-DRB1 TLR4 ERCC6 STAT4 IKZF1 FGFR2 STX16 BTD BTK RAG1 BTD PIK3R1 USB1 TNFRSF1A B2M GTF2E2 GNAS NLRP3 ICOS GNAS RAG2 AP1B1 HLCS LBR KLRC4 ZMPSTE24 IL10 UBAC2 BTK IGHM HLA-B DKC1 CD79B C4A PLG IL12A-AS1 IL12A IL23R DNASE1L3 BTNL2 NLRP1 IGSF3 UROS SLC39A4 MEFV DDB2 FERMT1 MAB21L1 TCF3 SCN9A MMP1 COL7A1 MBTPS2 GJB2 IGHM NLRP3 POLH Protein Mutations 0
SNP 0
Primary Outcomes
Description: - to asses virus RNA and miRNA levels in tears
Measure: virus molecular analysis Time: 2 weeksDescription: - to asses inflammatory response molecules
Measure: host molecular analysis Time: 2 weeksSecondary Outcomes
Description: To analyze the prevalence of conjunctivitis in patients with a diagnosis of COVID-19 and the assessment of the predictive value of conjunctivitis in the development of the COVID-19 disease (or in developing respiratory distress forms-ARDS).
Measure: Epidemiologic data Time: 2 weeks